Ligand
@Ligand_LGNDThe official X channel for Ligand Pharmaceuticals Incorporated.
Similar User
@SunKingGlobal
@DDT_Store
@SeamlessAI
@TalentLMS
@OmniAbTech
@CFLNewsHub
@SemperisTech
@GabinMarignier
@ECLTFoundation
@SnorkelAI
@OfficialKBRG
@CQU1929
@TellimerHQ
@MindSporeOSS
@iRemedyCorp
On November 19 our CEO Todd Davis and CFO Tavo Espinoza will present a company overview at the @StifeInst 2024 Healthcare Conference. Todd and Tavo will review Ligand’s business strategy, recent investment activity, and pipeline partner wins. bit.ly/3Axtuki
Today, we recognize the incredible courage and dedication of our veterans, who have safeguarded our freedoms. Your contributions remind us every day of the true meaning of sacrifice and honor. Thank you for your unwavering service. #VeteransDay
On today’s earnings call, Ligand’s leadership team highlighted the company’s strong business momentum and portfolio royalty revenue growth as key drivers for raising guidance for the second time this year. View our earnings release here: bit.ly/4fdmI2f
We will be hosting our annual Investor Day in Boston on December 10. A live webcast and replay will be available. To learn more and register: lifescievents.com/event/ligandph…
Huge congratulations to @Merck on the @CDCgov #ACIP recommendation of CAPVAXIVE™ for adults 50 and older. We are thrilled to have this vaccine as part of our growing #royalty portfolio at Ligand. Read more: x.com/Merck/status/1…
Today, the CDC’s Advisory Committee on Immunization Practices (#ACIP) voted to update the adult pneumococcal vaccination recommendations, expanding access to those at risk of #pneumococcal disease. Learn more: merck.us/3YpTDcK
Ligand will report Q3 2024 financial results before the opening of the U.S. financial markets on November 7 followed by a conference call at 8:30am ET. Register: bit.ly/48r7Tq3
Fantastic achievement @TravereRare and @CSL FILSPARI® has been approved by Swissmedic for the treatment of adults with primary IgA nephropathy. x.com/TravereRare/st…
Today we announced with CSL Vifor that Swissmedic has approved FILSPARI® (sparsentan) for the treatment of #IgAnephropathy (#IgAN). #InRareForLife Press release: bit.ly/402PX2V
We’re pleased to share new Phase 3 data in #pneumococcal disease at #IDWeek2024. Learn more: merck.us/3Yo8rcV
NEWS: #Rwanda today started the world's first clinical trial for Marburg virus disease treatments, in partnership with WHO. The trial involves testing the safety and efficacy of Remdesivir—a drug against viruses already used to treat COVID-19, and MBP091—a special antibody…
We are pleased to see @GileadSciences #remdesivir, which is formulated with Ligand's @captisol_info, has been donated for emergency use to support Rwanda’s response to the Marburg Virus Disease outbreak. Read more here: ow.ly/TVVZ50TKSt2
Ligand partner Palvella Therapeutics awarded up to $2.6 million grant by #FDA Office of Orphan Products Development to advance the development of QTORIN™ for the treatment of microcystic lymphatic malformations. ow.ly/6rIB50TCn4n
Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines. Read more: primrosebio.com/primrose-bio-a… #mRNA #vaccines #therapeutics
On Tuesday, September 10 our CEO Todd Davis and CFO Tavo Espinoza will present a company overview at the @HCWCO Annual Global Investment Conference in New York. View the press release here: bit.ly/3WRrfiI
Join us at 4:30pm ET today as Ligand’s senior management team discusses our quarterly financial results. View our earnings release and access our conference call information here: bit.ly/3Wzl9DA
Ligand partner Palvella Therapeutics announces merger agreement with @PierisPharma to fund Phase 3 development of QTORIN™ rapamycin. Ligand is entitled to a royalty of 8-9.8% on worldwide commercial sales. palvellatx.com/2024/07/24/pal…
Ligand will report Q2 2024 financial results after the close of the U.S. financial markets on August 6 followed by a conference call at 4:30pm ET. Register: bit.ly/3WzcOB3
Ligand Makes Second Big Oncology Investment In 2024 With Apeiron Buyout. The company is acquiring rights to royalties from Qarziba, a neuroblastoma drug approved in ex-US markets that Recordati develops and... Related StoriesNovo... ow.ly/kcAy105zUnK #PharmaScrip
Great story on Ligand’s @captisol_info technology platform in the current issue of @LawrenceBizMag x.com/LawrenceBizMag…
Did you know that animals may soon be able to benefit from the same stability, absorption and delivery methods of drugs offered to humans? It’s all happening at @KuInnovation Discover more in “From Molecule to Market” from our 2024 Q2 edition at lawrencebusinessmagazine.com/2024/06/19/fro….
Ligand hires Michael Vigilante and Ruben Flores-Saaib to expand the company’s investment and business development capabilities. bit.ly/3zHlnAK
Ligand has agreed to acquire @apeironbio, which holds royalty rights to QARZIBA®, the only immunotherapy for high-risk pediatric neuroblastoma marketed across Europe and in other parts of the world, for $100 million. bit.ly/45XfoDZ
United States Trends
- 1. Cowboys 53,8 B posts
- 2. Cooper Rush 10,1 B posts
- 3. Texans 52,5 B posts
- 4. #WWERaw 58,4 B posts
- 5. Mike McCarthy 2.073 posts
- 6. Trey Lance 2.269 posts
- 7. Sixers 9.856 posts
- 8. Mixon 12,9 B posts
- 9. Pulisic 19,1 B posts
- 10. #HOUvsDAL 7.760 posts
- 11. Derek Barnett 1.429 posts
- 12. Aubrey 15,1 B posts
- 13. Pitre 1.212 posts
- 14. #USMNT 3.277 posts
- 15. Keon Ellis N/A
- 16. #AskShadow 6.094 posts
- 17. Turpin 3.097 posts
- 18. Guyton 1.152 posts
- 19. CJ Stroud 3.371 posts
- 20. CeeDee 4.208 posts
Who to follow
-
Sun King
@SunKingGlobal -
DDT Store
@DDT_Store -
Seamless.AI
@SeamlessAI -
TalentLMS
@TalentLMS -
OmniAb
@OmniAbTech -
CFLNewsHub
@CFLNewsHub -
Semperis
@SemperisTech -
Brother Gabin
@GabinMarignier -
The ECLT Foundation
@ECLTFoundation -
Snorkel AI
@SnorkelAI -
KB Recording Group
@OfficialKBRG -
Chongqing University
@CQU1929 -
Tellimer
@TellimerHQ -
MindSpore
@MindSporeOSS -
iRemedy Healthcare
@iRemedyCorp
Something went wrong.
Something went wrong.